Research programme: metabotropic glutamate receptor antagonists - NovartisAlternative Names: MPEP
Latest Information Update: 01 Apr 2011
At a glance
- Originator Novartis
- Class Benzimidazoles; Nicotinic-acids
- Mechanism of Action Metabotropic glutamate receptor 5 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Anxiety disorders; Parkinson's disease